Drug Chatter -- Tracking biopharma stock chatter

DrugPatentWatch - Biopharmaceutical Business Intelligence

Profile for Five Prime Therapeutics, Inc. (FPRX)

« Back to company index

FPRX Chatter Timeline

Stock Ticker for FPRX

Most Active Tweeters for FPRX

UserTweets
@dailypoliticaln 3
@AmericanBanking 3
@ZolmaxNews 2
@mmahotstuff1 2
@bibeypost_stock 2

Recent Tweets for FPRX

mmahotstuff1 @mmahotstuff1
$-1.25 EPS Expected for Five Prime Therapeutics, Inc. $FPRX - https://t.co/8cvagNwfk9
July 14th 2018, 8:07am
whatsonthorold2 @whatsonthorold2
$-1.25 EPS Expected for Five Prime Therapeutics, Inc. $FPRX - https://t.co/AYoBNtK0Xx
July 14th 2018, 8:07am
ledgerzette @ledgerzette
Five Prime Therapeutics Inc $FPRX Expected to Post Earnings of -$1.25 Per Share https://t.co/UH2kUsmTbt
July 12th 2018, 4:07pm
TheMarketsDaily @TheMarketsDaily
Five Prime Therapeutics Inc $FPRX Expected to Announce Quarterly Sales of $5.87 Million https://t.co/nG8WevZtmh
July 12th 2018, 4:07pm
bibeypost_stock @bibeypost_stock
2.33 is Five Prime Therapeutics Inc's $FPRX Institutional Investor Sentiment - https://t.co/JsxAZmyC0Q
July 11th 2018, 1:07pm
mmahotstuff1 @mmahotstuff1
Five Prime Therapeutics Inc $FPRX: Stock Institutional Investors Are Bullish About - https://t.co/Ql2eeb3GXV
July 11th 2018, 1:07pm
bibeypost_stock @bibeypost_stock
Were Analysts Bullish Five Prime Therapeutics, Inc. $FPRX This Week? - https://t.co/RSF9nfMU5i
July 11th 2018, 12:07pm
portefeuillefun @portefeuillefun
Sold 500 $FPRX at $17.05, now 1300 #vssporte shares.
July 11th 2018, 11:07am
dakotafinancial @dakotafinancial
Five Prime Therapeutics Inc $FPRX Expected to Post Earnings of -$1.25 Per Share https://t.co/VUfn7u3DgB
July 10th 2018, 7:07am
dailypoliticaln @dailypoliticaln
Zacks: Brokerages Anticipate Five Prime Therapeutics Inc $FPRX Will Post Earnings of -$1.25 Per Share https://t.co/nDnhffYngP
July 10th 2018, 7:07am
dispatchtribune @dispatchtribune
Five Prime Therapeutics Inc $FPRX Receives Average Recommendation of “Hold” from Analysts https://t.co/LE17CMAHlZ
July 10th 2018, 12:07am
EnterpriseLeade @EnterpriseLeade
Five Prime Therapeutics Inc $FPRX Receives $34.71 Average Price Target from Analysts https://t.co/ARAedqxYRg
July 10th 2018, 12:07am
MareaInformativ @MareaInformativ
Zacks: Analysts Anticipate Five Prime Therapeutics Inc $FPRX Will Post Quarterly Sales of $5.87 Million https://t.co/5QRvj2syPm
July 9th 2018, 6:07am
AmericanBanking @AmericanBanking
Zacks: Analysts Anticipate Five Prime Therapeutics Inc $FPRX Will Post Quarterly Sales of $5.87 Million https://t.co/6xsxtHeZPK #stocks
July 9th 2018, 3:07am
ConsumerFeed @ConsumerFeed
Zacks: Analysts Anticipate Five Prime Therapeutics Inc $FPRX Will Post Quarterly Sales of $5.87 Million https://t.co/yhtKsPw2vt
July 9th 2018, 3:07am
TheMarketsDaily @TheMarketsDaily
Brokerages Set Five Prime Therapeutics Inc $FPRX Price Target at $34.71 https://t.co/BSIuhApS0Z
July 7th 2018, 11:07am
ZolmaxNews @ZolmaxNews
Brokerages Anticipate Five Prime Therapeutics Inc $FPRX Will Post Earnings of -$1.25 Per Share https://t.co/4dLcqN3fc7
July 7th 2018, 8:07am
AmericanBanking @AmericanBanking
Brokerages Anticipate Five Prime Therapeutics Inc $FPRX Will Post Earnings of -$1.25 Per Share https://t.co/LvAL8Jq9df #stocks
July 7th 2018, 8:07am
InnDeptInvestor @InnDeptInvestor
Expect $FPRX #FIVEPRIME_fprx back into mid $20s when China trade tensions stop making the news or get settled. Fair… https://t.co/kwv6UCLZIR
July 5th 2018, 12:07pm
ZolmaxNews @ZolmaxNews
Five Prime Therapeutics Inc $FPRX Receives $34.71 Average PT from Brokerages https://t.co/q8g3BXxK3q
July 5th 2018, 9:07am
dailypoliticaln @dailypoliticaln
Brokerages Set Five Prime Therapeutics Inc $FPRX Price Target at $34.71 https://t.co/vJL5oNpHmc
July 5th 2018, 9:07am
stb8444 @stb8444
$cala $fprx still have almost identical charts
July 5th 2018, 2:07am
AmericanBanking @AmericanBanking
Five Prime Therapeutics Inc $FPRX Given Consensus Rating of “Hold” by Brokerages https://t.co/r1PbuftFxb #stocks
July 2nd 2018, 7:07pm
ConsumerFeed @ConsumerFeed
Five Prime Therapeutics Inc $FPRX Given Consensus Rating of “Hold” by Brokerages https://t.co/kaVXzTenQc
July 2nd 2018, 7:07pm
TickerReport @TickerReport
Five Prime Therapeutics $FPRX Coverage Initiated by Analysts at Raymond James https://t.co/Y3mxGky6EO
July 2nd 2018, 2:07am
dailypoliticaln @dailypoliticaln
Five Prime Therapeutics $FPRX Coverage Initiated by Analysts at Raymond James https://t.co/MeEF1GUt9k
July 2nd 2018, 2:07am
WeekHerald @WeekHerald
Five Prime Therapeutics $FPRX Earns Market Perform Rating from Analysts at Raymond James https://t.co/Uuo4N7Rj84
July 1st 2018, 9:07am
ThisLincolnian @ThisLincolnian
Five Prime Therapeutics $FPRX Coverage Initiated at Raymond James https://t.co/xl0akDQY6C
July 1st 2018, 9:07am
registrarjourn @registrarjourn
Five Prime Therapeutics $FPRX Shares Down 1.7% https://t.co/w8R0LtyhPi
July 1st 2018, 4:07am
dakotafinancial @dakotafinancial
Five Prime Therapeutics $FPRX Trading Down 1.7% https://t.co/DhWplrJDZN
July 1st 2018, 4:07am
ledgerzette @ledgerzette
Five Prime Therapeutics $FPRX Now Covered by Raymond James https://t.co/fLlxb3vGGi
June 30th 2018, 9:06am
dakotafinancial @dakotafinancial
Five Prime Therapeutics $FPRX Now Covered by Analysts at Raymond James https://t.co/PNqg4BCpDt
June 30th 2018, 8:06am
TranscriptDaily @TranscriptDaily
Five Prime Therapeutics $FPRX Stock Rating Upgraded by BidaskClub https://t.co/LuXo8zboaG
June 30th 2018, 8:06am
EnterpriseLeade @EnterpriseLeade
Five Prime Therapeutics Inc $FPRX Expected to Announce Earnings of -$1.42 Per Share https://t.co/lRvuaqVE1u
June 30th 2018, 8:06am
stocknewstimes @stocknewstimes
Five Prime Therapeutics $FPRX Downgraded by Zacks Investment Research https://t.co/UkIH0KDnTI #stocks
June 30th 2018, 8:06am
stocknewstimes @stocknewstimes
Five Prime Therapeutics $FPRX Lifted to “Buy” at BidaskClub https://t.co/bZSbNQPnm2 #stocks
June 30th 2018, 8:06am
SleekMoneycom @SleekMoneycom
Five Prime Therapeutics $FPRX Downgraded by Zacks Investment Research https://t.co/zweZEHksuW #investing
June 30th 2018, 8:06am
SleekMoneycom @SleekMoneycom
Five Prime Therapeutics $FPRX Lifted to “Buy” at BidaskClub https://t.co/HLTOrMY7L1 #investing
June 30th 2018, 8:06am
registrarjourn @registrarjourn
Five Prime Therapeutics $FPRX Reaches New 12-Month Low at $15.32 https://t.co/6borJ1Zmpb
June 30th 2018, 7:06am
dakotafinancial @dakotafinancial
Five Prime Therapeutics $FPRX Reaches New 12-Month Low at $15.32 https://t.co/XKzlzOsKeL
June 30th 2018, 6:06am
TheMarketsDaily @TheMarketsDaily
Five Prime Therapeutics $FPRX Sets New 12-Month Low at $15.32 https://t.co/oCB1rzXHcT
June 30th 2018, 6:06am
OlympiaReport @OlympiaReport
Five Prime Therapeutics $FPRX Now Covered by Analysts at Raymond James https://t.co/6VKvh7FkAo
June 29th 2018, 8:06pm
OlympiaReport @OlympiaReport
Recent Investment Analysts’ Ratings Changes for Five Prime Therapeutics $FPRX https://t.co/xCtlmneC2h
June 29th 2018, 6:06pm
dispatchtribune @dispatchtribune
Recent Investment Analysts’ Ratings Changes for Five Prime Therapeutics $FPRX https://t.co/X2m9dDdNs9
June 29th 2018, 5:06pm
CFinancialNews @CFinancialNews
Recent Investment Analysts’ Ratings Changes for Five Prime Therapeutics $FPRX https://t.co/BWWmkApOfD #markets
June 29th 2018, 5:06pm
AmericanBanking @AmericanBanking
Recent Investment Analysts’ Ratings Changes for Five Prime Therapeutics $FPRX https://t.co/5MlRRBtwzF #stocks
June 29th 2018, 5:06pm
ThisLincolnian @ThisLincolnian
Five Prime Therapeutics $FPRX Rating Lowered to Hold at Zacks Investment Research https://t.co/cIH0KkSnKK
June 29th 2018, 6:06am
ConsumerFeed @ConsumerFeed
Five Prime Therapeutics $FPRX Rating Lowered to Hold at Zacks Investment Research https://t.co/zTN0QVXQk4
June 29th 2018, 3:06am
bibeypost_stock @bibeypost_stock
Five Prime Therapeutics $FPRX Receives Coverage From Raymond James. What Is The Stock’s Upside? - https://t.co/fXo8gIaK6A
June 29th 2018, 1:06am
reurope_stock @reurope_stock
How Will Five Prime Therapeutics $FPRX Stock React to The Latest Coverage By Raymond James? https://t.co/G5i5ne68HR
June 29th 2018, 1:06am

DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC 2004 - 2018. All rights reserved.